Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Jun 5, 2019 (7 years ago)

Cetirizine HCL Oral Solution 1 mg/mL

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

cGMP Deviations: Firm was notified by their supplier of Cetirizine HCL Oral Solution, USP, 1mg/mL, 4oz, of the voluntary recall that they have initiated due to potential contamination with Burkholderia cepacia (B.cepacia) and Ralstonia pickettii (R. pickettii).

Cause type: Microbial contamination

Bacteria, mold, yeast or other microorganisms detected in the product. Contamination can occur from water systems, equipment or handling, and can cause infection. All microbial contamination recalls.

What was recalled

Cetirizine HCL Oral Solution 1 mg/mL, Children's Allergy, Antihistamine, Dye Free, Gluten Free, Grape Flavor, 5 mg/5mL, 4 FL. oz. Bottle, Distributed by Dolgencorp, LLC, 100 mission ridge, Goodlettsville, TN 37072, NDC 55910-878-04, UPC 359726178051.

Affected NDC 55910-0878-04

Compare with the code on your package — it is the most precise check available.

Drug: Cetirizine Category: Allergy & Cold Medication

Recalling firm
P & L Developments, LLC
NDC code
55910-878-04
Origin
NY, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1407-2019 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Cetirizine recalls

See all
Class I · High risk

Cetirizine Hydrochloride Tablets USP 5 mg

Cross Contamination with Other Products: Customer complaints for appearance of discolored tablets and red dots observed on Cetirizine Hydrochloride Tablets USP 5 mg. Determined to be Ranitidine.

Ongoing Cross-contamination JB Chemicals and Pharmaceuticals Ltd NDC 16571-401-10 D-0732-2026

Other recalls by P & L Developments, LLC

All 2019 recalls
Class III · Low risk

Nicotine Gum

Labeling: Incorrect or Missing Package Insert: The package insert included in the finished product is for the Canadian market and is not part of the current approved drug labeling.

Terminated Labeling / mix-up P & L Developments, LLC NDC 11822-3328-3 D-0004-2021
Class II · Moderate risk

Cetirizine Oral Solution 1 mg/mL

cGMP Deviations: Firm was notified by their supplier of Cetirizine HCL Oral Solution, USP, 1mg/mL, 4oz, of the voluntary recall that they have initiated due to potential contamination with Burkholderia cepacia (B.cepacia) and Ralstonia pickettii (R. pickettii).

Terminated Microbial contamination P & L Developments, LLC NDC 11673-178-04 D-1409-2019
Class II · Moderate risk

Cetirizine Oral Solution 1 mg/mL

cGMP Deviations: Firm was notified by their supplier of Cetirizine HCL Oral Solution, USP, 1mg/mL, 4oz, of the voluntary recall that they have initiated due to potential contamination with Burkholderia cepacia (B.cepacia) and Ralstonia pickettii (R. pickettii).

Terminated Microbial contamination P & L Developments, LLC NDC 63868-430-04 D-1408-2019